Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of jaktinib versus hydroxycarbamide in intermediate-2/high-risk myelofibrosis
ChiCTR2100047040Phase 3Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of jaktinib and hydroxyurea in primary myelofibrosis (PMF) and myelofibrosis (MF) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Spleen volume response rate at week 24. Started Apr 2021; status: recruiting.
02
Drugs
jaktinibhydroxyurea
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on ChiCTR2100047040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047040.